Sales of stem cell products in the United States reached $16.4 million last year and are expected to surpass $35 million in 2007, according to Robin R. Young, a medical industry
analyst who has been named one of The Wall Street Journal’s “Best on the Street” and among the top-10 analysts in the United States by Institutional Investor.

The products, derived from allogenic or autologous stem/progenitor cells, are used primarily by orthopedic surgeons to stimulate bone growth in cases involving spinal repair (fusion and nucleus repair), fresh fractures and non-union fractures. More than 200 companies are preparing products for commercialization, including several stem cell therapies expected to enter the market in the coming 24-36 months for use in joint and cartilage repair cases.

At the 2nd Annual Stem Cell Summit, which is set for Feb. 12 and 13 in San Diego, Young will kick off the largest gathering of stem cell company executives, scientists, investors and physicians with the presentation of a 10-year forecast for the use of stem/progenitor cells in cardiology, orthopedics, oncology, urology and other markets. The forecast will consist of stem cell product shipment, average selling price and revenue
projections.

For more information about the stem cell
products, contact Young via e-mail at robin@ryortho.com or call
877-817-6450. For more information about the 2nd Annual Stem Cell Summit,
visit http://www.stemcellsummit.com.

SOURCE RRY Publications